Search
Black cohosh
go.drugbank.com/drugs/DB13975Approved[L2303] Hormone replacement therapy (HRT) is the standard treatment for early symptoms in post-menopausal women, however, increases the risk of stroke, heart diseases, as well as breast cancer in older
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAtobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985.
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalResorcinol works by helping to remove hard, scaly, or roughened skin.
Mixtures: Budpak Feminine Anti-ItchHNM01
go.drugbank.com/drugs/DB06531ExperimentalIt entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.
Pramipexole
go.drugbank.com/drugs/DB00413ApprovedInvestigationalIt was first approved by the FDA in 1997 [L5882]. … RLS is a sleep-related disorder characterized by unpleasant sensations in the lower extremities, often accompanied by an uncontrollable urge to move the legs [A176876].
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approvedIt is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigational(VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709ApprovedThe product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound